"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"

PHASE3CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
Ocular Redness
Interventions
DRUG

Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation

Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.

DRUG

Lumify® (brimonidine tartrate ophthalmic solution 0.025%)

Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.

Trial Locations (6)

28150

Bausch Site 03, Shelby

33119

Bausch Site 02, Memphis

40206

Bausch Site 05, Louisville

80907

Bausch Site 04, Colorado Springs

84015

Bausch Site 06, Clinton

01810

Bausch Site 01, Andover

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY